Clarius Group, LLC Denali Therapeutics Inc. Transaction History

Clarius Group, LLC

$1.64 Billion
Q3 2025

A detailed history of Clarius Group, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Clarius Group, LLC holds 359,745 shares of DNLI stock, worth $6.21 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares

359,745

Previous 368,995 2.51%

Holding current value

$6.21 Million

Previous $5.16 Million 1.18%

% of portfolio

0.32%

Previous 0.31%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 10, 2025	SELL	$12.75 - $15.65 $117,937 - $144,762	-9,250 Reduced 2.51%	359,745 $5.22 Million
Q1 2025 Apr 18, 2025	SELL	$13.6 - $23.59 $557,600 - $967,190	-41,000 Reduced 10.0%	368,995 $5.02 Million
Q2 2024 Jul 11, 2024	BUY	$14.96 - $23.22 $265,943 - $412,781	17,777 Added 4.53%	409,995 $9.52 Million
Q1 2024 Apr 17, 2024	BUY	$15.83 - $23.35 $220,923 - $325,872	13,956 Added 3.69%	392,218 $8.05 Million
Q3 2023 Oct 19, 2023	SELL	$20.63 - $30.17 $103 - $150	-5 Reduced -0.0%	378,262 $7.8 Million
Q2 2023 Aug 09, 2023	BUY	$23.37 - $32.96 $2.06 Million - $2.9 Million	87,937 Added 30.29%	378,267 $11.2 Million
Q1 2023 Apr 17, 2023	BUY	$21.91 - $32.67 $651,296 - $971,148	29,726 Added 11.41%	290,330 $6.69 Million
Q3 2022 Oct 24, 2022	BUY	$25.97 - $38.53 $6.03 Million - $8.94 Million	232,085 Added 813.79%	260,604 $8 Million
Q2 2022 Aug 10, 2022	BUY	$20.88 - $35.19 $43,305 - $72,984	2,074 Added 7.84%	28,519 $839,000
Q4 2021 Feb 02, 2022	BUY	$42.59 - $55.02 $585,612 - $756,525	13,750 Added 108.31%	26,445 $1.18 Million
Q3 2021 Oct 18, 2021	BUY	$48.48 - $78.23 $415,085 - $669,805	8,562 Added 207.16%	12,695 $640,000
Q2 2021 Aug 06, 2021	BUY	$50.3 - $78.44 $207,889 - $324,192	4,133 New	4,133 $324,000

Others Institutions Holding DNLI

# of Institutions

248

Shares Held

135M

Call Options Held

148K

Put Options Held

15.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.31B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clarius Group, LLC with notifications on news.

Account

Clarius Group, LLC Denali Therapeutics Inc. Transaction History